August 2012
-
While acknowledging the 60th anniversary of the metered dose inhaler, the 27th annual Drug Delivery to the Lungs meeting devoted much of its program to looking forward beyond conventional devices, formulations, and targets. More than… Read more . . .
-
Lonza Group will acquire capsule manufacturer and CDMO Capsugel from KKR for $5.5 billion, the company has announced. The deal has been approved by the boards of both companies and is expected to close by… Read more . . .
-
Cephalgia, a startup spun out of the University of Chicago, will receive $250,000 from the university’s Innovation Fund for development of intranasal IGF-1 for the treatment of migraine, according to the fund. The company was… Read more . . .
-
Propeller Health has announced that its inhaler monitoring platform will integrate with mobile and clinical spirometers from Medical International Research (MIR). According to Propeller, its platform “is the only commercially marketed respiratory digital health solution… Read more . . .
-
Adherium has announced that its Smartinhaler has been selected for use in the myAirCoach project, which will study the effectiveness of mHealth systems for asthma control. The program, which includes participation by Imperial College London,… Read more . . .
-
Following the signing of an international phase-down agreement regarding fluorinated gases in October 2016, pMDI propellent supplier Mexichem stated that it “does not believe the recent Kigali Amendment to the Montreal Protocol, nor regulatory controls… Read more . . .
-
H&T Presspart and Cohero Health have officially launched the eMDI connected metered dose inhaler (eMDI), which integrates with Cohero Health’s BreatheSmart inhaler tracking and lung function measurement platform. The two companies initially announced the eMDI… Read more . . .
-
OINDP development specialist Nanopharm has appointed Arron Danson as Head of Device Development, the company said. Danson has extensive experience in the development of pulmonary and nasal delivery devices, having worked at companies such as… Read more . . .
-
GlaxoSmithKline and Innoviva have announced that GSK has filed an MAA with the European Medicines Agency for its fluticasone furoate/umeclidinium/vilanterol DPI for the treatment of COPD. In November 2016, GSK submitted an NDA for the… Read more . . .
-
Intranasal drug developer Impel NeuroPharma has received $21 million in the initial tranche of a Series C financing round, with another $15 million available on completion of development and business milestones, the company said. Investors… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland